The Inositol Polyphosphate 5-Phosphatase PIPP Regulates AKT1-Dependent Breast Cancer Growth and Metastasis  by Ooms, Lisa M. et al.
ArticleThe Inositol Polyphosphate 5-Phosphatase PIPP
Regulates AKT1-Dependent Breast Cancer Growth
and MetastasisGraphical AbstractHighlightsd Pipp knockout promotes oncogene-driven breast cancer
initiation and growth
d Ablation of Pipp impairs metastasis in a mouse model of
breast cancer
d PIPP regulates AKT1-dependent cell migration and invasion
d Low PIPP expression is associated with ER-negative breast
cancer and poor prognosisOoms et al., 2015, Cancer Cell 28, 155–169
August 10, 2015 ª2015 Elsevier Inc.
http://dx.doi.org/10.1016/j.ccell.2015.07.003Authors
Lisa M. Ooms, Lauren C. Binge,
Elizabeth M. Davies, ..., Paul Timpson,
Catriona A. McLean, Christina A.
Mitchell
Correspondence
christina.mitchell@monash.edu
In Brief
Ooms et al. identify the inositol
polyphosphate 5-phosphatase PIPP as a
suppressor of oncogenic PI3K/AKT
signaling in breast cancer. PIPP depletion
increases transformation and accelerates
oncogene-driven tumor growth in vivo,
while paradoxically reducing cell
migration, invasion, and metastasis.
Cancer Cell
ArticleThe Inositol Polyphosphate 5-Phosphatase PIPP
Regulates AKT1-Dependent Breast Cancer Growth
and Metastasis
Lisa M. Ooms,1,5 Lauren C. Binge,1,5 Elizabeth M. Davies,1 Parvin Rahman,1 James R.W. Conway,2 Rajendra Gurung,1
Daniel T. Ferguson,1 Antonella Papa,1 Clare G. Fedele,1,6 Jessica L. Vieusseux,1,7 Ryan C. Chai,1 Frank Koentgen,3
John T. Price,1,8 Tony Tiganis,1 Paul Timpson,2 Catriona A. McLean,4 and Christina A. Mitchell1,*
1Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3800, Australia
2Garvan Institute of Medical Research, The Kinghorn Cancer Centre, Faculty of Medicine, St Vincent’s Clinical School, University of NSW,
Darlinghurst, NSW 2010, Australia
3Ozgene Pty Ltd, Bentley DC, WA 6983, Australia
4Department of Anatomical Pathology, Alfred Hospital, Prahran, VIC 3181, Australia
5Co-first author
6Present address: Melanoma Research Laboratory, Peter MacCallum Cancer Centre, East Melbourne, VIC 3002, Australia
7Present address: Metastasis Research Laboratory, Peter MacCallum Cancer Centre, East Melbourne, VIC 3002, Australia
8Present address: College of Health and Biomedicine, Victoria University, St Albans, VIC 3021, Australia
*Correspondence: christina.mitchell@monash.edu
http://dx.doi.org/10.1016/j.ccell.2015.07.003SUMMARYMetastasis is the major cause of breast cancer mortality. Phosphoinositide 3-kinase (PI3K) generated
PtdIns(3,4,5)P3 activates AKT, which promotes breast cancer cell proliferation and regulates migration. To
date, none of the inositol polyphosphate 5-phosphatases that inhibit PI3K/AKT signaling have been reported
as tumor suppressors in breast cancer. Here, we show depletion of the inositol polyphosphate 5-phospha-
tase PIPP (INPP5J) increases breast cancer cell transformation, but reduces cell migration and invasion.Pipp
ablation accelerates oncogene-driven breast cancer tumor growth in vivo, but paradoxically reduces metas-
tasis by regulating AKT1-dependent tumor cell migration. PIPP mRNA expression is reduced in human ER-
negative breast cancers associated with reduced long-term outcome. Collectively, our findings identify PIPP
as a suppressor of oncogenic PI3K/AKT signaling in breast cancer.INTRODUCTION
In response to growth factor stimulation, activated class 1 phos-
phoinositide 3-kinase (PI3K) generates phosphatidylinositol
3,4,5-trisphosphate (PtdIns(3,4,5)P3) that facilitates the activa-
tion of many effectors, including the serine/threonine kinase
AKT (Miller et al., 2011; Yuan and Cantley, 2008). PI3K/AKT
signaling drives cell proliferation and survival. PIK3CA, the
gene that encodes the catalytic (p110a) subunit of class 1
PI3K, is mutated and activated in 35%–45% of luminal A
(ER-positive (ER+) and/or PR+) and 29% of luminal B (ER+ and/orSignificance
Breast cancer is the most common cancer in women. Despite
disease, the leading cause of breast cancer death. The phosph
tivated in breast cancer and represents a significant target for
regulator of PI3K signaling, promotes oncogene-driven breas
mRNA expression is decreased in ER-negative primary breas
survival. Our studies suggest that analysis of PIPP expression
that would benefit from therapies targeting the PI3K signalingPR+, HER2+/) breast cancers (Sabine et al., 2014; Cancer
Genome Atlas Network, 2012). Transgenic overexpression of
mutant Pik3ca or endogenous knock in of Pik3caH1047R in murine
mammary glands leads to the spontaneous development of
breast tumors (Liu et al., 2011; Meyer et al., 2011; Tikoo et al.,
2012). Many PI3K mutations that occur in cancer are associated
with poor outcomes, however, in breast cancer, the prognostic
role of PIK3CA mutations is still emerging. Indeed, for reasons
that remain unclear, expression of some PIK3CA mutants in
luminal tumors may be associated with improved long-term sur-
vival (Dumont et al., 2012; Kalinsky et al., 2009).advances in treatments, many patients develop metastatic
oinositide 3-kinase signaling pathway is frequently hyperac-
novel therapies. Here, we show that loss of Pipp, a negative
t cancer initiation and growth, but impairs metastasis. PIPP
t cancers associated with reduced relapse-free and overall
in human breast cancers may identify a subset of patients
pathway.
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Figure 1. PIPP Depletion Enhances Cell Proliferation, Survival, and Tumorigenic Potential
(A) Control shRNA, PIPP shRNA (1), and (2) expressing MDA-MB-231 cells were serum-starved for 24 hr or 48 hr. The BrdU incorporation was assessed as a
marker of cell proliferation. The data represent the average percentage of BrdU positive cells ± SEM, n = 4.
(B) MDA-MB-231 cells expressing control orPIPP shRNA (1) orPIPP shRNA (2) were grown in serum for 24 hr then treatedwith 1 mMstaurosporine (STS) or DMSO
for 6 hr. The apoptotic cells were identified by TUNEL staining. The data represent mean TUNEL positive nuclei ± SEM, n = 3.
(C) Control andPIPP shRNA (1) expressingMDA-MB-231 cells were suspended in soft agar ± the pan-AKT inhibitor AktX (5 mM) to assess anchorage independent
cell growth. The number of colonies/well relative to untreated control shRNA expressing cells ± SEM was determined from five experiments performed in
triplicate.
(legend continued on next page)
156 Cancer Cell 28, 155–169, August 10, 2015 ª2015 Elsevier Inc.
PI3K signaling is terminated by phosphoinositide phospha-
tases, such as the tumor suppressor PTEN, which hydrolyzes
PtdIns(3,4,5)P3 to form PtdIns(4,5)P2 and thereby suppresses
AKT activation. Germline mutations in PTEN in Cowden’s syn-
drome are associated with a 25%–50% lifetime risk of breast
cancer (Hollander et al., 2011). In addition, PTEN loss is
observed in 30%–40% of sporadic cases of breast cancer
associated with AKT hyperactivation and tumor progression
(Zhang et al., 2013). Interestingly, an alternative pathway for
the termination of PI3K signaling is mediated by inositol poly-
phosphate 5-phosphatases (5-phosphatase), which degrade
PtdIns(3,4,5)P3 to form PtdIns(3,4)P2, and in turn 4-phospha-
tases, such as INPP4B, hydrolyze PtdIns(3,4)P2 to form PI(3)P
(Astle et al., 2007; Ooms et al., 2009). Although INPP4B is a
potential tumor suppressor, to date there is no evidence that
any of the ten mammalian 5-phosphatases suppress oncogenic
PI3K/AKT signaling in breast cancer.
The proline rich inositol polyphosphate 5-phosphatase, PIPP,
dephosphorylates PtdIns(3,4,5)P3 to suppress AKT activation
and oppose oncogenic PI3K signaling in cultured fibroblasts
(Denley et al., 2009; Ooms et al., 2006). The gene encoding hu-
man PIPP (INPP5J) is located on chromosome 22q12. Allelic
loss of chromosome 22q12 occurs in 30% of breast tumors
(Ellsworth et al., 2003; Iida et al., 1998; Osborne and Hamshere,
2000) and loss of heterozygosity (LOH) of chromosome 22q is
frequent in breast carcinomas (Castells et al., 2000; Ellsworth
et al., 2003; Iida et al., 1998). LOH of D22S1150 and D22S280,
which map to either side of the PIPP gene, has been detected
in 41 and 45% of breast carcinomas, respectively (Allione
et al., 1998). In addition, PIPP mRNA expression is decreased
in estrogen receptor-negative (ER) breast cancers compared
to ER+ tumors (Gruvberger et al., 2001; van ’t Veer et al.,
2002). However, whether PIPP acts as a tumor suppressor in
regulating breast tumor growth, metastasis, and long-term sur-
vival has not been reported. In this study, we examined the
role PIPP plays in breast cancer progression.
RESULTS
Decreased PIPP Expression Promotes Cell Proliferation
and Survival
To investigate PIPP regulation of breast cancer cell proliferation
and tumor growth, stable PIPP short hairpin (sh)RNA-mediated
knockdown was undertaken in the ER MDA-MB-231 human
breast cancer cell line. There were two distinct PIPP-specific
shRNAs (PIPP shRNA [1] and [2]; Figure S1A) that resulted
in 45%–55% and 60%–70% knockdown of PIPP mRNA
expression, respectively, as assessed by quantitative RT-PCR
(Figure S1B) and immunoblotting (Figure S1C). PIPP shRNA(D) Mean colony size of PIPP shRNA (1) expressing MDA-MB-231 cells suspende
from three experiments performed in triplicate.
(E–G) MDA-MB-231-luc cells expressing control or PIPP-specific shRNAs were
growth assessed over 4 weeks. The imaging of tumors in vivo (E) and ex vivo (F) a
shRNA knockdown cells formed larger tumors in vivo. The average tumor volum
(n = 9) ± SEM are shown.
(H) MDA-MB-231 cells expressing control, PIPP shRNA (1), or PIPP shRNA (2) we
times (min). The lysates were immunoblotted with antibodies specific for pAKTS
blots are representative of four experiments. The scale bars represent 2mm (C), 5
Figure S1.knockdown enhanced cell proliferation (1.3–1.7-fold) under con-
ditions of serum-starvation (24–48 hr) (Figure 1A), but had no
effect on the proliferation of MDA-MB-231 cells grown in serum
(Figure S1D). PIPP depletion was associated with decreased
apoptosis (6.8–7.7-fold) in response to staurosporine treat-
ment (Figure 1B). The decrease in apoptosis was rescued by
transient overexpression of exogenous wild-type, but not cata-
lytically inactive shRNA-resistant HA-PIPP (Figure S1E), consis-
tent with the inhibition of apoptosis by PIPP being dependent
on its 5-phosphatase activity. The ability of cells to exhibit
anchorage independent cell growth in soft agar is a feature of
cell transformation. PIPP shRNA promoted anchorage indepen-
dent cell growth with a significant increase in both the size
(4-fold) and number of colonies (2.5-fold) formed compared
to control cells (Figures 1C and 1D). To assess whether PIPP reg-
ulates breast cancer growth in vivo, MDA-MB-231-luc cells ex-
pressing PIPP or control shRNA were injected into the mammary
fat pads of athymic nude mice and tumor growth was measured
over 4 weeks. PIPP knockdown increased tumor size 2.6–3.3-
fold compared to vector controls (Figures 1E–1G).
ActivatedAKTdrivescell proliferationand inhibits apoptosis via
phosphorylation of downstream effectors, such as GSK3b. PIPP
shRNA knockdown increased phospho-AKTSer473 (pAKTSer473)
and pAKTThr308 relative to total AKT and phospho-GSK3bSer9/
GSK3b following epidermal growth factor (EGF) stimulation, sug-
gesting PIPP suppresses AKT signaling in breast cancer cells
(Figure 1H). In addition,PIPP shRNAknockdown increasedphos-
phorylation of PRAS40 and other immunoreactive proteins de-
tected by a phospho-AKT substrate antibody (Ivetac et al.,
2009) (Figure S1F). The increased phosphorylation of AKT and
AKT substrates in PIPP shRNA cells was suppressed by treat-
ment with the PI3K inhibitor BKM120 (Figure S1F). Furthermore,
the increased soft agar colony formation observed with PIPP
knockdown was inhibited by the pan-AKT inhibitor, AktX (Fig-
ure 1C). Therefore, PIPP depletion promotes breast cancer cell
proliferation, survival, and transformation in vitro and tumor
growth in a xenograft mouse model.
To confirm the effects of PIPP depletion on ER breast cancer
cells,PIPP knockdownwas also undertaken in the triple negative
breast cancer cell line, Hs578T, resulting in 65% PIPP knock-
down as assessed by quantitative RT-PCR (Figure S1G). PIPP
shRNA knockdown enhanced cell proliferation (2.0–2.3-fold) un-
der conditions of serum-starvation (Figure S1H) and increased
the number of colonies formed (1.7-fold) in anchorage indepen-
dent cell growth assays (Figure S1I). In addition, PIPP shRNA
knockdown increased pAKTSer473 relative to total AKT following
EGF stimulation (Figure S1J), consistent with the effects
observed with PIPP depletion in MDA-MB-231 triple negative
breast cancer cells.d in soft agar relative to control shRNA expressing cells ± SEMwas determined
injected into the mammary fat pads of athymic BALB/c nude mice and tumor
nd quantification of tumor volume by calliper measurements (G) revealed PIPP
es from control shRNA (n = 9), PIPP shRNA (1) (n = 10), and PIPP shRNA (2)
re serum-starved overnight then stimulated with 20 ng/ml EGF for the indicated
er473, pAKTThr308, pGSK3bSer9, or total AKT or GSK3b as loading controls. The
00 mm (D), and 10mm (E and F) (*p < 0.05, **p < 0.01, and ***p < 0.001). See also
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Loss of Pipp Does Not Affect Mammary Gland
Development
To assess the role PIPP plays in mammary development and
tumorigenesis in vivo, we generated mice with a Pipp allele in
which the second exon was flanked with loxP recombination
sites (Pippfl/fl). The phenotype of Pipp knockout mice has not
been reported to date. Pippfl/fl mice were crossed with CMV-
Cre mice, resulting in Pipp deletion in all tissues (Figure S2).
Absence of Pipp mRNA expression was shown by quantitative
RT-PCR (Figure 2A). Pipp/ mice were viable and born at the
expected Mendelian frequency. Pipp/ mice were fertile and
displayed no overt phenotype at 4 months of age. PI3K/AKT
signaling contributes to mammary gland morphogenesis, how-
ever, Pipp/ mammary glands (4 and 7 weeks) exhibited no
abnormalities in terminal end bud number, ductal branching,
morphology, or outgrowth into the mammary fat pad (Figures
2B–2D), suggesting that Pipp expression is not essential for mu-
rine mammary gland development. The outer layer of CK14 pos-
itive basal cells and inner layer of CK18 positive luminal epithelial
cells within the ducts were unchanged in Pipp/ breast tissue
(Figures 2E and 2F). Transgenic mice expressing constitutively
active AKT or mice with conditional loss of Pten in the mammary
gland exhibit delayed mammary gland involution following
weaning (Li et al., 2002; Schwertfeger et al., 2001). At day 2 of
involution, alveolar structures were apparent in wild-type and
Pipp/ mice (Figure 2G). By day 5 of involution, alveolar struc-
tures were collapsed and adipocytes reappeared equally irre-
spective of Pipp expression, suggesting that PIPP does not
regulate involution (Figure 2G). Pik3ca expression or loss of
Pten leads to spontaneous mammary tumor formation in mice
(Liu et al., 2011; Meyer et al., 2011; Tikoo et al., 2012). However,
Pipp/mice showed no evidence of mammary gland hyperpla-
sia at 1 year of age (n = 8) (Figure 2H) or mammary tumors up to
20 months of age (Pipp+/+ n = 4 and Pipp/ n = 14). Therefore,
loss of Pipp expression by itself in murine mammary tissue does
not affect mammary gland development or promote initiation of
de novo breast cancer.
PIPP Regulates Oncogene-Driven Breast Cancer
Initiation and Primary Tumor Progression
As murine Pipp ablation per se did not lead to spontaneous
mammary tumors, we investigated the consequences of loss
of this 5-phosphatase in an oncogene-driven mammary cancer
mouse model. Polyoma middle T (PyMT) oncogene expression
in mammary epithelium leads to multifocal mammary tumor for-
mation and drives activation of Ras and PI3K/AKT signaling. The
MMTV-PyMTmurine mammary tumor model exhibits character-
istics of the ER+ luminal subtype of human breast cancer,
associated with four identifiable stages of tumor progression
(hyperplasia, adenoma, early carcinoma, and late carcinoma)
analogous to human breast tumors, followed by high frequency
of metastasis to the lung (Lin et al., 2003). MMTV-PyMT male
mice were mated with female Pipp+/ mice to generate
PyMT;Pipp+/+ and PyMT;Pipp/ mice (Figure 3A). Hyperplasia
was detected in the mammary gland of control animals at
45 days and, notably, the number of hyperplastic foci in mam-
mary fat pads of PyMT;Pipp/mice was increased5-fold (Fig-
ures 3B and 3C). In addition, the area of hyperplasia was
increased at 45 (3-fold) and 70 (2.4-fold) days in PyMT;Pipp/158 Cancer Cell 28, 155–169, August 10, 2015 ª2015 Elsevier Inc.mammary glands (Figures 3B and 3D), suggesting that Pipp
ablation promotes breast cancer initiation. Pipp ablation signifi-
cantly increased cell proliferation in PyMT-induced hyperplastic
lesions (Figures 3E and 3F), associated with a significant in-
crease in pAKT and pGSK3b staining intensity in the hyperplastic
foci (Figures 3G and 3H).
To assess the effect of Pipp ablation onmammary cancer pro-
gression, tumor growth in PyMT;Pipp+/+ and PyMT;Pipp/mice
was measured twice weekly after tumor onset. The change in
volume of the largest tumor in each mouse and the total tumor
burden was significantly increased in PyMT;Pipp/ relative to
PyMT;Pipp+/+ breast tumors (Figure 4A) and was associated
with increased cell proliferation as shown by Ki67 staining (Fig-
ure 4B). In advanced tumors, the highest pAKT and pGSK3b
staining was observed in tumor cells near the interface with sur-
rounding mammary tissue in both PyMT;Pipp+/+ and PyMT;
Pipp/ mice, but was more intense in PyMT;Pipp/ tumors
(Figures 4C and 4D).
AKT activation is facilitated by PtdIns(3,4,5)P3, which is
dephosphorylated by PIPP to generate PtdIns(3,4)P2. Both
PtdIns(3,4,5)P3 and PtdIns(3,4)P2 are required for full AKT activa-
tion, however, the depletion of other PtdIns(3,4,5)P3 5-phospha-
tases, such as SHIP1, SHIP2, INPP5E, and SKIP leads to
enhanced AKT activation, suggesting increased levels of
PtdIns(3,4,5)P3 alone may be sufficient to activate AKT (Dyson
et al., 2012; Ooms et al., 2009). The effect of Pipp ablation on
plasma membrane phosphoinositide signals was assessed by
immunofluorescence microscopy using PtdIns(3,4,5)P3 and
PtdIns(3,4)P2 antibodies and phosphoinositide-specific biosen-
sors. Plasma membrane PtdIns(3,4,5)P3 signals were increased
(1.2-fold) following growth factor stimulation in cell lines estab-
lished from PyMT;Pipp/ primary tumors and MDA-MB-231
PIPP shRNA knockdown cells compared to controls (Figures
S3A and S3B). In addition, increased plasma membrane recruit-
ment (1.26-fold) of the PtdIns(3,4,5)P3 biosensor GFP-PH/Btk
was observed in PyMT;Pipp/ tumor cells following insulin-
like growth factor 1 (IGF-I) stimulation (Figure S3C). Conversely,
plasma membrane PtdIns(3,4)P2 signals were decreased fol-
lowing growth factor stimulation in PyMT;Pipp/ tumor cells
(1.18-fold) and MDA-MB-231 PIPP shRNA knockdown cells
(1.38-fold) relative to controls at the same time point (Figures
S3D and S3E). Furthermore, Pipp ablation impaired the plasma
membrane recruitment of the PtdIns(3,4)P2 biosensor YFP-PH/
TAPP1 in response to IGF-I stimulation (Figure S3F).
In control studies, immunohistochemistry (IHC) staining of tu-
mor sections revealed expression of the PyMT oncoprotein was
similar in PyMT;Pipp/ and PyMT;Pipp+/+ mammary glands
(Figure 4E). Therefore Pipp ablation in MMTV-PyMTmice signif-
icantly enhances primary mammary cancer initiation and tumor
progression.
PIPP Regulates Cancer Cell Migration and Metastasis
Despite recent advances in breast cancer therapy, metastasis
remains the leading cause of breast cancer death (Dumont
et al., 2012). The MMTV-PyMTmouse model develops lung me-
tastases at high frequency (Guy et al., 1992). To determine the in-
fluence of Pipp expression on metastasis, PyMT;Pipp+/+ and
PyMT;Pipp/ lung tissue sections were examined for the pres-
ence of lung metastases. All mice developed lung metastases,
Figure 2. Pipp–/– Mice Exhibit Normal Mammary Development
(A) Pipp exon 2 expression was quantified by quantitative (q)RT-PCR relative to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in mRNA extracted from
brains of Pipp+/+ versus Pipp/ mice. The data represent mean Pipp expression ± SEM, n = 3 mice/genotype (*p < 0.05).
(B) Carmine alum stained mammary gland whole mounts from virgin Pipp+/+ and Pipp/mice at 28 and 49 days of age. The data represent the mean percentage
invasion of the epithelial tree into the mammary fat pad ± SEM from 28 (Pipp+/+ n = 3 and Pipp/ n = 4) and 49 day (Pipp+/+ n = 5 and Pipp/ n = 7) mice (lymph
node, LN).
(C) Magnified images of Carmine alum stained mammary gland whole mounts from 28- and 49-day-old Pipp+/+ and Pipp/ mice showing terminal end buds
(TEB). The data represent the mean number of TEB/gland ± SEM from 28- (Pipp+/+ n = 3 and Pipp/ n = 4) and 49-day-old (Pipp+/+ n = 5 and Pipp/ n = 7) mice.
(D) Mammary gland whole mounts were prepared as above from 16-week-old Pipp+/+ and Pipp/mice. The data represent the mean number of branch points ±
SEM from Pipp+/+ (n = 12) and Pipp/ (n = 11) mice.
(E and F) Formalin fixed, paraffin embedded (FFPE) sections of fourth mammary glands from 16-week-old Pipp+/+ and Pipp/ mice were stained with hema-
toxylin and eosin (H&E) (E) or immunostained with CK14 (green) and CK18 (red) antibodies and counterstained with To-Pro-3 to detect nuclei (blue) (F).
(G) Hematoxylin and eosin (H&E) stained, formalin fixed, paraffin embedded (FFPE) mammary gland sections from Pipp+/+ and Pipp/ mice at 2 and 5 days
involution.
(H) Carmine alum stained mammary gland whole mounts from 1-year-old Pipp+/+ and Pipp/ mice. The scale bars represent 2 mm (B), 1 mm (C, D, and H),
100 mm (E and G), and 50 mm (F). See also Figure S2.
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Figure 3. Pipp Ablation Promotes Tumor Initiation in PyMT Model Mice
(A)Pipp exon 2 expression was quantified by qRT-PCR relative to GAPDH inmRNA extracted frommammary tumors ofPyMT;Pipp+/+ versusPyMT;Pipp/mice.
The data represent mean Pipp expression ± SEM, n = 7 mice/genotype.
(B–D) Pipp ablation is associated with increased numbers and size of hyperplastic foci (arrows) in the mammary glands of 45- and 70-day-old PyMTmice (B). The
data represent the mean number of hyperplastic foci per mammary gland ± SEM from 45-day-old PyMT;Pipp+/+ (n = 6) and PyMT;Pipp/ (n = 6) mice (C). The
total area of hyperplastic foci in mammary gland whole mounts was measured using ImageJ. The data represent the mean area of hyperplasia ± SEM from 45-
(n = 6 mice/genotype) and 70-day-old (PyMT;Pipp+/+ n = 8 and PyMT;Pipp/ n = 9) mice (D).
(E and F) Ki67 immunostaining of mammary gland sections from 45- and 70-day-old PyMT;Pipp+/+ and PyMT;Pipp/ mice (E). The data represent the mean
percentage of Ki67 positive cells ± SEM in the hyperplastic lesions of 45 (PyMT;Pipp+/+ n = 6 and PyMT;Pipp/ n = 5) and 70-day-old (PyMT;Pipp+/+ n = 8 and
PyMT;Pipp/ n = 9) mice (F).
(G and H) Representative images of pAKTSer473 (G) and pGSK3bSer9 (H) immunostaining of mammary gland sections from 45- and 70-day-old PyMT;Pipp+/+ and
PyMT;Pipp/ mice. The scale bars represent 2 mm (B) and 100 mm (E, G, and H) (*p < 0.05, **p < 0.01, and ***p < 0.001).irrespective of Pipp status. Interestingly however, the total num-
ber of lung metastases was significantly lower in PyMT;Pipp/
compared to PyMT;Pipp+/+ mice (4.3-fold decrease) (Figures
5A and 5B). Therefore, loss of Pipp impairs breast cancer metas-
tasis despite promoting increased primary tumor growth.
AsPipp ablation impairedmammary cancermetastasis in vivo,
we next examined whether loss of PIPP affected breast cancer
cell growth and invasion using organotypic assays. Control
and PIPP shRNA knockdown MDA-MB-231 cells were seeded
onto organotypic matrices consisting of human fibroblast-
contracted rat tail collagen and cultured for 10 or 14 days.160 Cancer Cell 28, 155–169, August 10, 2015 ª2015 Elsevier Inc.PIPP depletion did not affect the fraction of cells in the upper
section of the matrix (0–100 mm), but significantly reduced
the percentage of invading cells at both 10 and 14 days
(Figures 5C and 5D). In addition, PIPP shRNA expressing
MDA-MB-231 cells above the matrix exhibited increased cell
proliferation after 10 days, but no change in the number
of apoptotic cells (Figures 5E, 5F, and S4). These results suggest
thatPIPP depletion promotes breast cancer cell proliferation, but
impairs invasion, consistent with the increased primary tumor
growth, but decreased metastasis observed in PyMT;Pipp/
mice.
Figure 4. Pipp Ablation Promotes Tumor Growth in PyMT Model Mice
(A) Graphs show the mean volume ± SEM of the largest tumor per mouse and total tumor volume (mm3) after diagnosis (time 0) from PyMT;Pipp+/+ (n = 12) and
PyMT;Pipp/ (n = 10) mice. The largest tumor in all mice exhibited the same size (100 mm3) at diagnosis (time 0).
(B) Ki67 staining of mammary tumor sections. The data represent the mean percentage of Ki67 positive cells ± SEM in tumors from seven mice/genotype.
(C and D) Representative images of tumor sections from PyMT;Pipp+/+ and PyMT;Pipp/ mice stained with antibodies specific for pAKTSer473 (C) or
pGSK3bSer9 (D).
(E) Representative images of mammary gland sections from PyMT;Pipp+/+ and PyMT;Pipp/ mice stained with an antibody specific for PyMT. The scale bars
represent 100 mm (B and E) and 50 mm (C and D) (*p < 0.05 and **p < 0.01). See also Figure S3.AKT is a major effector of oncogenic PI3K signaling in cancer.
There are three AKT isoforms, AKT1, AKT2, and AKT3, that have
been identified, each with non-redundant functions in breast
cancer. A hotspot mutation, E17K, occurs in AKT1 in 3%–8%
of breast cancers (Carpten et al., 2007; Kim et al., 2008) and
AKT3 is upregulated in triple negative breast cancers (Chin
et al., 2014a). In breast cancer, particularly in the context of
metastasis, there is emerging evidence that AKT1 and AKT2
play distinct functional roles. For example, expression of consti-
tutively active AKT1 in murine mammary tissue does not drive de
novo mammary tumor formation (Dillon et al., 2009; Hutchinson
et al., 2004). However, in transgenic oncogene-driven murinemodels of breast cancer, AKT1 induces primary tumor growth,
but inhibits metastasis in vivo (Dillon et al., 2009; Hutchinson
et al., 2004). In contrast, the results from analysis of Akt1
knockout mice are conflicting, with one study demonstrating
reduced lung metastases and another increased metastases in
MMTV-neu mice (Ju et al., 2007; Maroulakou et al., 2007). On
the other hand, expression of constitutively active AKT2 pro-
motes metastasis in murine breast cancer models (Dillon et al.,
2009). To determine whether the reduction in metastasis
observed in PyMT;Pipp/ mice was associated with impaired
cancer cell migration, we evaluated cell migration in scratch
wound healing assays using MDA-MB-231 control and PIPPCancer Cell 28, 155–169, August 10, 2015 ª2015 Elsevier Inc. 161
Figure 5. Pipp Depletion Impairs Breast Cancer Metastasis and Cell Invasion
(A and B) Formalin fixed, paraffin embedded (FFPE) lung sections from PyMT;Pipp+/+ and PyMT;Pipp/mice were stained with hematoxylin and eosin (H&E) to
identify metastases (arrows) (A). The data represent the mean total number of metastases from five lung sections/mouse ± SEM from PyMT;Pipp+/+ (n = 11) and
PyMT;Pipp/ (n = 10) mice (B).
(C and D) Control shRNA or PIPP shRNA (1) expressing MDA-MB-231 cells were seeded onto organotypic matrices, cultured for 10 or 14 days, and stained for
multi-cytokeratin (C), arrows indicate invading cells. The average number of invasive cells at 0–100 mm, 100–200 mm, 200–300 mm, and >300 mmwere counted in
ten representative images and normalized to the number of cells on top of the organotypic matrix. The results are expressed relative to control shRNA expressing
cells at each depth, which were arbitrarily assigned a value of one. The data represent mean ± SEM, n = 5 (D).
(E and F) Representative images of organotypic matrices seeded with MDA-MB-231 cells and stained for Ki67 (E). The percentage of proliferating cells on top or
within the matrix was quantified in ten representative images normalized to the total number of cells present after 10 or 14 days invasion. The data represent
mean ± SEM, n = 5 (F). The scale bars represent 500 mm (A) and 50 mm (C and E) (*p < 0.05 and ***p < 0.001). See also Figure S4.shRNA knockdown cells. PIPP shRNA knockdown significantly
reduced wound healing with 50%–60% wound closure after
36 hr compared to 90% closure in controls (Figures 6A and
6B). Individual cell tracking revealed control cells migrated in a
directedmanner into thewound. In contrast,PIPP shRNA knock-
down cells exhibited random migration and cells traveled
perpendicular to, rather than migrating into, the wound (Fig-
ure 6C). PIPP depletion also impaired cell migration toward a
chemoattractant (3.2-fold decrease), a phenotype partially
rescued by treatment with the pan-AKT inhibitor, AktX (Figures
6D and 6E). To confirm these observations, cell lines were estab-
lished from PyMT;Pipp/ and PyMT;Pipp+/+ primary mammary162 Cancer Cell 28, 155–169, August 10, 2015 ª2015 Elsevier Inc.tumors. PyMT;Pipp/ tumor cells exhibited a 3.5-fold decrease
in migration toward a chemoattractant (Figures 6F, 6G, and S5)
that was in part rescued by treatment with AktX (Figures 6F
and 6G). These results suggest that the cell migration defect
observed in PIPP-deficient cells is a consequence of dysregu-
lated AKT signaling.
PIPP Regulates NFAT1, TSC2, and Mmp2 Expression
As AKT1 and AKT2 play opposing roles in regulating cell migra-
tion and metastasis, we next examined whether the cell migra-
tion defect in PIPP-deficient cells was AKT isoform-dependent.
Droplet digital PCR analysis revealed Akt1 as the predominant
Figure 6. PIPP Depletion Impairs Breast Cancer Cell Migration
(A–C) Confluent monolayers of MDA-MB-231 cells expressing control or PIPP shRNA (1) or (2) were wounded, and cell migration into the woundmonitored by live
cell microscopy. The representative images show the same area at 0 hr and after 36 hr incubation (A). The data represent mean percentagewound closure ± SEM,
n = 3 (B). The migration of individual cells over 36 hr was tracked using ImageJ (C) (nR 20 cells/sample, representative of three experiments).
(D and E) Migration of control and PIPP shRNA (1) expressing MDA-MB-231 cells toward a serum gradient was measured using Transwell assays ± a pan-AKT
inhibitor, AktX (D). The results are expressed relative to untreated control shRNA expressing cells. The data represent mean ± SEM, n = 4 (E).
(F and G) Epithelial tumor cell lines were established from mammary tumors from PyMT;Pipp+/+ and PyMT;Pipp/ mice. The cell migration toward a serum
gradient was determined using Transwell assays ± AktX (F). The results are expressed relative to untreated PyMT;Pipp+/+ cells. The data represent mean ± SEM,
n = 3 (G). The scale bars represent 250 mm (A) and 100 mm (D and F) (*p < 0.05 and **p < 0.01). See also Figure S5.isoform expressed in PyMT;Pipp mammary tumor epithelial cell
lines (Figure 7A). MDA-MB-231 cells exhibited similar levels of
AKT1 and AKT2 expression (Figure S6A). AKT isoform expres-
sion was not affected by PIPP depletion in either PyMT;Pipp
mammary tumor epithelial or MDA-MB-231 cells (Figures 7A
and S6A). To assess whether PIPP depletion results in differen-
tial AKT isoform activation, MDA-MB-231 shRNA cells were im-
munoblotted with pAKT1 versus pAKT2-specific antibodies as
described (Chew et al., 2015; Chin et al., 2014b). Phosphoryla-
tion of both AKT1 and AKT2 was increased in MDA-MB-231PIPP shRNA cells in response to EGF stimulation (Figure S1F),
suggesting PIPP inhibition of AKT activation is not isoform
specific.
To determine whether AKT1 or AKT2 was responsible for the
observed cell migration defect in PIPP-deficient cells, shRNA-
mediated knock down of Akt1 or Akt2 was undertaken in PyMT:
Pippmammary tumor cell lines resulting in 73%–89% and 67%–
91% knock down, respectively (Figures S6B–S6D). Notably,
PyMT;Pipp/ cell migration was restored to wild-type levels
by shRNA knock down of Akt1, but not Akt2 (Figures 7B and 7C).Cancer Cell 28, 155–169, August 10, 2015 ª2015 Elsevier Inc. 163
Figure 7. Pipp Knockout Impairs AKT1-Mediated Migration in PyMT;Pipp Tumor Cells
(A) Absolute Akt1, Akt2, and Akt3 expression was quantified by droplet digital PCR in mRNA extracted from PyMT;Pipp+/+ versus PyMT;Pipp/ mammary
epithelial tumor cell lines. The data represent mean Akt isoform expression ± SEM, n = 3.
(legend continued on next page)
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AKT1 inhibits the migration of breast cancer cells, and thereby
invasion andmetastasis, by regulating the protein levels or activ-
ity of several effectors (Chin and Toker, 2009). AKT1 phosphory-
lates and, thereby, destabilizes the tumor suppressor tuberous
sclerosis complex 2 (TSC2), a Rho-GTPase regulator that influ-
ences cell migration via regulation of F-actin assembly (Astrinidis
et al., 2002). AKT1 also phosphorylates and regulates the protein
levels of NFAT1, a pro-invasion transcription factor (Yoeli-Lerner
et al., 2005, 2009). Furthermore, AKT1 phosphorylates palladin
and promotes its actin-bundling function (Toker, 2012). To
assess the effects of loss of PIPP on AKT1 downstream effec-
tors, PyMT;Pipp/ tumor and MDA-MB-231 PIPP shRNA cell
lines were analyzed for NFAT1 and TSC2 protein expression by
immunoblot analysis, revealing decreased protein levels (Figures
7D–7G and S6E–S6J). PyMT;Pipp/ tumors also exhibited
significantly decreased NFAT1 positive nuclei compared to
PymT;Pipp+/+ tumors (Figures 7H and 7I).
Cancer cells invade through the extracellular matrix by de-
grading collagen type IV, a major structural component of the
basement membrane. Matrix metalloproteinase 2 (MMP2) di-
gests a number of substrates including collagen type IV and
gelatin and plays a role in breast cancer cell invasion and metas-
tasis (Chabottaux and Noel, 2007; Jezierska and Motyl, 2009).
AKT1 regulatesMMP2 expression in cultured breast cancer cells
(Park et al., 2001). PyMT;Pipp/ tumor-derived and MDA-MB-
231 PIPP shRNA cell lines exhibited reduced Mmp2 expression
relative to control cells (Figures 7J, S6K, and S6L). Consistent
with these observations, PyMT;Pipp/ tumor and MDA-MB-
231 PIPP shRNA cell lines showed reduced matrix degradation
(Figures 7K, 7L, S6M, and S6N). Therefore, we conclude that
loss of PIPP impairs breast cancer cell migration and matrix
degradation through increased AKT1 activity and, thereby,
decreased NFAT1, TSC2, and Mmp2 expression.
PIPP and AKT1mRNA Expression Is Decreased in ER–
Human Primary Breast Cancers
PIPPmRNAexpression isdecreased inER versusER+breast tu-
mors (Gruvberger et al., 2001; van ’t Veer et al., 2002), but PIPP
expression has not been correlated with breast cancer subtype.
Here, PIPP mRNA expression was evaluated using TissueScan
BreastCancer cDNAArrays I–IV (OriGene) of 16 normal breast tis-
sues and176primary humanbreast cancer samples.PIPPmRNA(B and C) Migration of PyMT;Pipp+/+ cells stably expressing non-target shRNA or
shRNAs toward a serum gradient was determined using Transwell assays (B). The
target shRNA. The data represent mean ± SEM, n = 4 (C).
(D) Lysates of mammary tumor cell lines from PyMT;Pipp+/+ and PyMT;Pipp/
loading control.
(E) Densitometric analysis of NFAT1 expression normalized to GAPDH. The resu
assigned a value of one. The data represent mean ± SEM, n = 3.
(F) Lysates of mammary tumor cell lines from PyMT;Pipp+/+ and PyMT;Pipp/
loading control.
(G) Densitometric analysis of TSC2 expression normalized to GAPDH. The resu
assigned a value of one. The data represent mean ± SEM, n = 5.
(H and I) Representative images of tumor sections from PyMT;Pipp+/+ and PyMT;P
the mean percentage of cells exhibiting NFAT1 positive nuclei ± SEM in tumors
(J)Mmp2 expression was quantified by qRT-PCR relative to GAPDH in mRNA ext
data represent mean Mmp2 expression ± SEM in tumor cell lines, n = 3.
(K and L)PyMT;Pipp tumor cells were plated on Texas red-labeled gelatin (red) coa
to label F-actin (K). The regions of matrix degradation appear as dark spots in the
SEM, n = 3 (L). The scale bars represent 100 mm (B), 50 mm (H), and 10 mm (K) (*expression was reduced in ER breast tumors relative to ER+ tu-
mors (Figure 8A). Luminal breast cancers express ER and/or PR
and in general have good outcomes, relative to triple negative
cancers (ER/PR/HER2), which exhibit poor prognosis (Voduc
et al., 2010). PIPPmRNA expression was significantly decreased
in triple negative breast cancers, relative to normal breast tissue
or luminal breast cancers (Figure 8B).
As PIPP depletion was identified here to inhibit AKT1-depen-
dent cell migration, we evaluated AKT1 expression in the same
breast cancer cohort. AKT1 expression also showed a positive
correlation with ER status (Figure 8A) and was significantly lower
in triple negative tumors relative to normal breast tissue or
luminal breast cancers (Figure 8B). Therefore, PIPP exhibits a
similar pattern of mRNA expression to AKT1 in human breast
cancers. To further explore the association between PIPP and
AKT1, we examined tumors with a >2-fold reduction in PIPP
and AKT1 expression relative to normal breast tissue. There
were 85% of ER+ breast cancers that showed PIPP/AKT1
expression comparable to normal breast tissue levels, whereas
71% of ER tumors exhibited low PIPP/AKT1mRNA expression
(p < 0.001; Figure 8C), suggesting that expression of both PIPP
and AKT1 is reduced in ER breast cancers. Examination of
the Kaplan-Meier-Plotter data set (Gyo¨rffy et al., 2010) revealed
that lower PIPP expression predicted for reduced relapse-free
and overall survival (Figures 8D and 8E).
DISCUSSION
Mutation of PIK3CA is one of the most common events in ER+
breast cancer (Ma and Ellis, 2013; Pang et al., 2014). Here, we
identify the inositol polyphosphate 5-phosphatase PIPP as a
suppressor of oncogenic PI3K/AKT signaling in breast cancer.
PIPP shRNA knockdown increased breast cancer cell prolifera-
tion, reduced apoptosis, increased anchorage independent cell
growth, and enhanced xenograft tumor growth, associated with
increased AKT signaling. PIPP also suppressed oncogenic PI3K/
AKT signaling in vivo. Pipp knockout in an oncogene-driven
murine breast cancer model increased primary breast tumor
growth, and the tumors showed increased AKT signaling. In
human breast tumors, PIPP expression was reduced in triple
negative breast cancers and was associated with reduced
long-term survival.PyMT;Pipp/ cells stably expressing non-target Akt1 (1) or (2) or Akt2 (1) or (2)
results are expressed relative to untreated PyMT;Pipp+/+ cells expressing non-
mice were immunoblotted with antibodies specific for NFAT1 or GAPDH as a
lts are expressed relative to PyMT;Pipp+/+ tumor cells, which were arbitrarily
mice were immunoblotted with antibodies specific for TSC2 or GAPDH as a
lts are expressed relative to PyMT;Pipp+/+ tumor cells, which were arbitrarily
ipp/mice stained with antibodies specific for NFAT1 (H). The data represent
from seven mice/genotype (I).
racted from PyMT;Pipp+/+ versus PyMT;Pipp/mammary tumor cell lines. The
ted coverslips for 48 hr then fixed and stained with Alexa 488-phalloidin (green)
Texas red gelatin images. The data represent mean area of degraded matrix ±
p < 0.05 and **p < 0.01). See also Figure S6.
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Figure 8. PIPP and AKT1 mRNA Expression Is Decreased in ER– Primary Human Breast Cancers
(A and B) Normalized PIPP and AKT1mRNA expression was determined by qRT-PCR using TissueScan Breast Cancer Arrays I-IV with PIPP, AKT1, and b-actin
primers. The data are displayed as box and whiskers on a log scale. The PIPP and AKT1 expression was correlated with (A) ER (140 cases) or (B) breast cancer
subtype (135 cases). p values were determined using a two-tailed Mann-Whitney test (*p < 0.05, **p < 0.01, and ***p < 0.001).
(C) Breast cancer cases were scored for normal (PIPP+/AKT1+) versus low (PIPP/AKT1) PIPP and AKT1mRNA expression in ER+ and ER tumors (75 cases).
The significance was determined using a Fisher’s exact test (p < 0.001).
(D and E) Correlation of PIPPmRNA levels with breast cancer survival. Kaplan-Meier plots of relapse-free (D) and overall (E) patient survival stratified by median
PIPP expression in the KM Plotter breast cancer meta-analysis database (Gyo¨rffy et al., 2010). The statistical significance was determined using a log rank test.This study has identified a breast tumor regulatory role for an
inositol polyphosphate 5-phosphatase. Although many of the
ten mammalian 5-phosphatases hydrolyze PtdIns(3,4,5)P3 and
suppress AKT signaling in cultured cells, a tumor suppressive
role for this enzyme family analogous to PTEN is slow to emerge.
The hematopoietic-specific SHIP1 is mutated in rare cases of
acute myeloid leukemia, associated with amplified PI3K/AKT
signaling and Ship1 knockout mice exhibit hematopoietic cell
expansion (reviewed in Ooms et al., 2009). The 5-phosphatase
SKIP suppresses PTEN-deficient U87MG cell proliferation, and
its increased expression predicts for improved outcomes in glio-
blastoma (Davies et al., 2014). PIPP expression is reduced in hu-
man melanomas, and ectopic expression or shRNA knock down
of PIPP in melanoma-derived cultured cell lines results in altered
cell proliferation and transformation (Ye et al., 2013). Recently,
PIPP was also identified as a target for micro-RNAs in squamous
cell carcinoma (Lin et al., 2014). However, no murine knockout
for Pipp has been reported and therefore its function as a tumor
suppressor in vivo has not been tested. Here, Pipp/ mice
showed normal mammary gland development and did not
develop mammary tumors. Notably, loss of Pipp in MMTV-
PyMT mice resulted in increased mammary hyperplasia, with
accelerated growth of hyperplastic foci and established tumors.
Similarly, constitutively active AKT1 expression also promotes
tumor cell proliferation and mammary tumor growth in MMTV-
neu mice (Young et al., 2008), but transgenic expression of
constitutively active AKT1 alone in the mammary gland does166 Cancer Cell 28, 155–169, August 10, 2015 ª2015 Elsevier Inc.not promote de novo tumor formation (Hutchinson et al., 2001;
Schwertfeger et al., 2001). The effects of Pipp ablation on tumor
development in MMTV-PyMT mice may be cell autonomous or
stromal-dependent, as Pipp was deleted in all tissues, including
the stroma. Xenograft studies using MDA-MB-231 cells with
PIPP knockdown suggest a cell autonomous role for PIPP in
suppressing mammary tumor development, however, further
studies will be required to delineate the effects of PIPP expres-
sion in stromal versus epithelial mammary cells.
Surprisingly, although Pipp ablation significantly increased
mammary tumor growth in MMTV-PyMT mice, this was associ-
ated with reduced lung metastases. However, it should be noted
that although PyMT;Pipp/mice exhibited decreased numbers
of metastases, loss of Pipp did not alter the percentage of mice
that developed lung metastases. It is conceivable that loss of
PIPP expression reduces the metastatic potential of human
breast cancers, however, the increased proliferative advantage
of any PIPP-deficient cells that do metastasize may facilitate
establishment and growth of tumor foci at distant sites. AKT1
and AKT2 exhibit opposing effects on breast cancer cell migra-
tion, invasion, and metastasis (Arboleda et al., 2003; Chin and
Toker, 2009; Yoeli-Lerner et al., 2005). Notably, AKT1 and
AKT2 are activated to the same extent by growth factor stimula-
tion and by the same upstream kinases and/or oncogenic PI3K.
We have no evidence that PIPP inhibits the activation of specific
AKT isoforms. Rather, as AKT1 is the dominant isoform in PyMT
breast cancer cells, as reported previously (Maroulakou et al.,
2007), it is likely PIPP loss of expression results in greater activa-
tion of the total AKT1 pool over AKT2. In addition, it is not clear
whether AKT1 exerts more significant effects on cell migration
and invasion than the opposing actions mediated by AKT2,
when both these kinases are co-expressed. Therefore, we pro-
pose in the experimental models used here, PIPP loss activates
AKT, which in turn suppresses cell migration through several
downstream effectors of AKT1 including TSC2 and NFAT1.
AKT1 promotes the degradation of TSC2, resulting in decreased
activation of Rho, and also regulates the stability and protein
expression of the transcription factor NFAT1 (Astrinidis et al.,
2002; Larkins et al., 2006; Yoeli-Lerner et al., 2005, 2009).
Expression of myristoylated AKT1 decreases TSC2 levels in
T4-2 breast cancer cells and tumor xenografts, resulting in cell
migration and invasion defects that are rescued by exogenous
TSC2 expression (Liu et al., 2006). AKT1 activation promotes
degradation of the transcription factor NFAT1 in a GSK3b-
dependent manner (Yoeli-Lerner et al., 2005, 2009). PIPP-
deficient cells exhibited significantly impaired cell migration
associated with reduced expression of AKT1-dependent effec-
tors NFAT1 and TSC2. Consistent with these observations,
pan-AKT inhibition and shRNA knock down of Akt1, but not
Akt2, rescued the cell migration defect in PIPP-deficient cells.
We propose a model whereby loss of Pipp expression in breast
cancers promotes AKT activation, leading to increased mam-
mary tumor growth, but impaired AKT1-dependent cell migration
and metastasis.
Notably, PIPP is expressed in ER+ human breast cancers, but
its expression is reduced in the poor prognosis triple negative
human breast cancer subtype. Low PIPP expression is
associated with poor long-term outcome, which appears coun-
terintuitive to our observation of reduced lung metastases in
PyMT;Pipp/ mice. However, this apparent paradox could be
explained by differences in AKT isoform expression and/or activ-
ity in primary human breast cancers. The relative expression of
AKT1 in human breast tumors is complex and may relate to the
breast cancer subtype. In our study of human tumors, AKT1
mRNA expression correlated with both ER status and PIPP
expression and was significantly decreased in triple negative
breast cancers. Several other studies, however, have reported
no correlation between AKT1 mRNA or protein expression and
ER status (Creighton, 2007; Grell et al., 2012; Sta˚l et al., 2003),
although pAKT1 levels were reported as higher in ER+ than
ER tumors (Gershtein et al., 2007). In addition, increased
AKT1 kinase activity has been reported in 45% of primary breast
cancers (Sun et al., 2001). It is interesting to speculate breast
cancers with decreased PIPP and AKT1 expression may still ex-
press activated AKT2, which in turn promotesmetastasis leading
to poorer outcomes.
Breast cancer deaths are most frequently caused by metasta-
tic disease rather than the primary tumor, therefore, understand-
ing the molecular mechanisms that regulate metastasis are
critically important. Identifying biomarkers of metastasis may
facilitate the development of effective tailored therapies to
improve patient outcomes. Collectively, our studies suggest
analysis of PIPP expression in breast cancer subtypes may iden-
tify a subset of patients that may benefit from PI3K inhibitor ther-
apy, however, the relative expression and activation of AKT1
may also impact on therapeutic decision making.EXPERIMENTAL PROCEDURES
MDA-MB-231 and Hs578T Cell Culture
MDA-MB-231 (ATCC) and MDA-MB-231-luc cells (Dr. John Price) were main-
tained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% fetal calf serum (FCS) (Invitrogen) (growth media). Hs578T cells were
maintained in RPMI 1640 supplemented with 10% FCS, 10 mg/ml insulin
(Sigma), and 20 mM HEPES.
Transwell Cell Migration Assays
Cells were seeded at 5 3 104 per well in the top chamber of a Transwell
in serum-free DMEM in duplicate. Cells were allowed to migrate toward
DMEM, 10% FCS for 3 hr (MDA-MB-231) or 24 hr (PyMT;Pipp tumor cell lines)
at 37C. For AKT inhibitor studies, 2.5 mMAktX was added to both the top and
bottom chambers of the Transwell. Non-migrated cells were removed from the
upper chamber surface with a cotton swab, and cells that had migrated to the
underside of the upper chamber were fixed and stained using a Diff-Quick
Staining Kit (Lab Aids P/L). Cells were imaged using a 320 objective on an
Olympus CKX41 light microscope. The average number of migrated cells
was scored from 12 fields/Transwell.
Generation of Pipp–/– Mice and PyMT;Pipp–/– Mice
Details of the mouse strains generated can be found in the Supplemental Infor-
mation. All procedures involving mice were conducted in accordance with
National Health and Medical Research Council (NHMRC) regulations on the
use and care of experimental animals and were approved by the Monash Uni-
versity Animal Ethics Committee (SOBSB/2006/57 and SOBSB/2008/14).
Statistical Analysis
TissueScan Breast Cancer Arrays were analyzed by a two-tailed Mann-
Whitney test. Tumor growth in PyMT;Pipp mice and phosphoinositide signals
were analyzed by two-way ANOVA with Bonferroni post-test. Transwell cell
migration assays, anchorage independent cell growth assays, and Akt shRNA
western blots were assessed by one-way ANOVA with Tukeys multiple
comparisons test. Droplet digital PCR assays were analyzed by two-way
ANOVA with Bonferroni post-test. All other p values were determined using
a Student’s t test.
Further or detailed experimental procedures are described in the Supple-
mental Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.ccell.2015.07.003.
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